Clinical studies recruiting near Salzburg

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Phase 2 · Investigational Site Number : 0400002 · Sanofi · NCT06867094 Austrian PBC Registry
Phase N/A · Universitätsklinikum Salzburg · Medical University of Vienna · NCT07598669 Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaf · Princess Maxima Center for Pediatric Oncology · NCT05327894 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Uniklinikum Salzburg-Universitätsklinik für Innere Medizin I · Merck Sharp & Dohme LLC · NCT06393374 XEN Glaucoma Gel Stent Versus Trabeculectomy
NA · Dept. Ophthalmology and Optometry Paracelsus Medical Univers · Prof. Dr. Herbert Reitsamer · NCT05439161 - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma
Phase 2 · SCRI CCCIT Ges.m.b.H. · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT06856837 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintena
Phase 3 · Uniklinikum Salzburg Landeskrankenhaus ( Site 0304) · Merck Sharp & Dohme LLC · NCT07216703 Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Respon
NA · Universitätsspital Salzburg · Klinik Hirslanden, Zurich · NCT04289935 A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary
Phase N/A · Praxis Gesundheitszentrum Moos 15 (Praxis Prof. Lichtenauer) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT06686615 A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · LKH - Universitätsklinikum der PMU Salzburg · Janssen Research & Development, LLC · NCT07499232 NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-
NA · Unfallkrankenhaus Salzburg · AUVA · NCT04474106 Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling
NA · University Hospital Salzburg · St George's, University of London · NCT04936620 A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Phase 3 · Universitaetsklinikum Salzburg Landeskrankenhaus · Janssen Research & Development, LLC · NCT06319820 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LK · AbbVie · NCT04928846 Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase 2/Phase 3 · Paracelsus Medical University Hospital Salzburg · Exelixis · NCT06943755 High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Phase 3 · Universitastsklinikum Salzburg · Gustave Roussy, Cancer Campus, Grand Paris · NCT04221035 A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre
Phase 3 · Investigative Site AT003 · Incyte Corporation · NCT07522073 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557 Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
NA · Uniklinikum Salzburg · Fundacio Clinic Barcelona · NCT06446882 A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treat
Phase 3 · Research Site · AstraZeneca · NCT06764875 An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ
Phase 3 · Investigational Site Number : 0400002 · Sanofi · NCT07184931 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · Universitätsklinikum Salzburg · Swiss GO Trial Group · NCT04111978 Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 3 · Universitatsklinik fur Innere Medizin 3 · Immunocore Ltd · NCT05549297 An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerabilit
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT07517263 Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Phase 3 · Landeskrankenhaus Salzburg, Universitätsklinik für Innere Me · University of Heidelberg Medical Center · NCT06216158 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Uniklinikum Salzburg ( Site 2956) · Merck Sharp & Dohme LLC · NCT03486873 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Phase 3 · LKH Salzburg, Universitätsklinik für Kinder- und Jugendheilk · University Hospital Muenster · NCT04043494 Fast Discharge After Acute Myocardial Infarction Discharge MI
NA · Paracelsus Medical University Salzburg · Medical University Innsbruck · NCT06744322 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A
Phase 2 · Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LK · AbbVie · NCT04895436 International Registry of Accidental Hypothermia
Phase N/A · Krankenhaus Barmherzige Brüder · University Hospital, Geneva · NCT06200285

Look up another city

Look up another condition